Pioneer in phage-based diagnostics

Twitter Youtube Linkedin Envelope
  • Home
  • About PBD Biotech
    • About
    • Research
    • Blog
  • Phage-based diagnostics
  • Animal Health
    • Animal Health
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Human Health
  • Contact us
  • Home
  • About PBD Biotech
    • About
    • Research
    • Blog
  • Phage-based diagnostics
  • Animal Health
    • Animal Health
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Human Health
  • Contact us

Actiphage TB test patent extended to West Africa

PBD Biotech has obtained grant of its patent application for its Actiphage® incipient tuberculosis diagnostic within the regional African Intellectual Property Organization (OAPI). This covers the mainly French-speaking countries of West Africa.
  • February 24, 2023
  • Corporate
Actiphage TB patent extended to West Africa

The Actiphage TB patent is for a unique diagnostic aimed at early-stage infection. Actiphage can identify live cells of Mycobacteria tuberculosis (M.tb) from a blood sample, providing evidence that a person is carrying an active tuberculosis infection that will progress to full disease unless treated (incipient TBI).

Improved diagnostics for identifying people with incipient TBI, before they show clinical symptoms of the disease, is a strategic priority in the WHO #EndTB strategy. PBD Biotech holds two patent portfolios in this area: 2015 ‘Mycobacteria detection using bacteriophages’, and 2020 ‘Methods relating to Tuberculosis’, which specifically covers its tests for incipient TB.

Jane Theaker, Chief Executive of PBD Biotech, says: “Actiphage offers a potential game-changer in the detection and treatment of people with incipient TB. By identifying those with active disease before they start to transmit the bacteria, it offers potential to break the cycle of infection.

“We are currently working in Zambia and South Africa on clinical studies. We are pleased to report on the grant of this patent as it provides evidence of our commitment to expand our operations and patent portfolio, while protecting our interests in this competitive market.”

The patent is supported by a study published in Clinical Infectious Diseases: ‘A Novel, High-sensitivity, Bacteriophage-based Assay Identifies Low-level Mycobacterium Tuberculosis Bacteraemia in Immunocompetent Patients with Active and Incipient Tuberculosis’ (DOI: 10.1093/cid/ciz548). The study was led by Raman Verma and Pranabashis Haldar of the National Institute for Health Research Respiratory Biomedical Research Centre at University of Leicester.

Using a novel, phage-based blood assay, the researchers reported the first concordant evidence to demonstrate associations of Mtb bacteraemia with progressive phenotypes of latent infection and active pulmonary tuberculosis (PTB). The researchers concluded that Actiphage offers promise as a blood-based diagnostic tool for infectious PTB to allow for earlier diagnoses in patients unable to expectorate sputum.

The study was in a well-characterized, immunocompetent human cohort and offered a sensitivity of 73% and specificity of 100% in symptomatic patients with suspected PTB. For all patients, Actiphage had a specificity of 94% with no change in sensitivity.

Actiphage was identified by the recent TAG Pipeline Report as the only test in development able to detect bacteraemia. It offers clear advantages as a rapid, low-cost assay that offers a microbiological diagnosis in the absence of sputum.

Share:

Related posts

Loading...
Laboratory Support from PBD Biotech

New qPCR kit offers rapid Mycobacterial detection

July 2, 2025
NEW - Lyophilised qPCR Kit for Mycobacterium tuberculosis Complex Detection
Laboratory Support from PBD Biotech

New qPCR kit offers rapid Mycobacterial detection

July 2, 2025
NEW - Lyophilised qPCR Kit for Mycobacterium tuberculosis Complex Detection
Actiphage TB diagnostic releases bacterial DNA for qPCR

Commercial opportunities with PBD Biotech

June 30, 2025
PBD Biotech is actively seeking commercial partnerships to exploit its patented technology.
Actiphage TB diagnostic releases bacterial DNA for qPCR

Commercial opportunities with PBD Biotech

June 30, 2025
PBD Biotech is actively seeking commercial partnerships to exploit its patented technology.
mycobacteria

Work by phage pioneers celebrated in World Antimicrobial Awareness Week

November 23, 2023
Dr Ben Swift has been awarded a Horizon award by AMI for his ground-breaking work developing a phage-based diagnostic for tuberculosis.
mycobacteria

Work by phage pioneers celebrated in World Antimicrobial Awareness Week

November 23, 2023
Dr Ben Swift has been awarded a Horizon award by AMI for his ground-breaking work developing a phage-based diagnostic for...
Certificate of Grant (web)

Actiphage TB patent granted in South Africa

November 14, 2023
Grant of a patent has been awarded to PBD Biotech for its Actiphage diagnostic for incipient tuberculosis in South Africa, this complements the regional West Africa patent gained earlier this year.
Certificate of Grant (web)

Actiphage TB patent granted in South Africa

November 14, 2023
Grant of a patent has been awarded to PBD Biotech for its Actiphage diagnostic for incipient tuberculosis in South Africa, this complements...
1 2 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
B4 Parkside Knowledge Gateway
Nesfield Road
Colchester
CO4 3ZL
United Kingdom

info@pbdbio.com

BIVDA member 2023
Twitter Youtube Linkedin

Privacy and cookies policy

© 2025 PBD Biotech Ltd

design: out of house